Program
ninerafaxstat
Also written as “IMB-1018972” and “Ninerafaxstat 200mg MR”.
Its studies are mostly in Cardiomyopathy, Hypertrophic · Angina Pectoris · Diabetes Mellitus, Type 2 · Ischemia, led by Imbria Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Imbria Pharmaceuticals | 51 open or running | phase 2since Mar 8, 2020 | Mar 8, 2020 | Dec 2026phase 2 · NCT07023614 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 8, 2020First study: phase 2 study in Angina PectorisFirst studyNCT04306237 · United States
- Mar 18, 20213 phase 2 studiesNCT04826185, NCT04826172, NCT04826159
- Jun 9, 2025Phase 2 study in Cardiomyopathy, HypertrophicNCT07023614 · 165 planned · United States, Austria, Belgium and more
Ahead
- Dec 2026Primary completion: phase 2 study in Cardiomyopathy, HypertrophicNCT07023614
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07023614Cardiomyopathy, Hypertrophic · United States, Austria, Belgium and more | 2 | Recruiting | Dec 2026 | 165 |
| NCT04826185Non-obstructive Hypertrophic Cardiomyopathy · United States, United Kingdom | 2 | Completed | Sep 18, 2023 | 67 |
| NCT04826172Ischemia · Denmark, Finland, Sweden | 2 | Completed | Sep 21, 2023 | 58 |
| NCT04826159Diabetes Mellitus, Type 2 · United Kingdom | 2 | Completed | Aug 6, 2024 | 49 |
| NCT04306237Angina Pectoris · United States | 2 | Withdrawn | Feb 2025 | 0 |
How it is read
Names in the registry
- “IMB-1018972”, 4 entries
- “Ninerafaxstat 200mg MR”, 1 entry
Conditions, from the studies’ own filings
- Cardiomyopathy, Hypertrophic, 2 studies
- Angina Pectoris, 1 study
- Diabetes Mellitus, Type 2, 1 study
- Ischemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.